CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

Golidocitinib

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionDec 26, 2025
Entity authorityQ131696536 ↗
Source-derived summary

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.

Editorial summary

The public source identifies “Golidocitinib” as pharmaceutical compound. This brief keeps that definition visible, then builds a research path around Golidocitinib, pharmaceutical and compound.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current lead gives the account dated anchors—2024—that can be checked directly. The selected authority fields contribute no independent date. Its value is orientation rather than verdict, with Golidocitinib, pharmaceutical and compound providing the first useful test.
Editorial analysis

Why this record matters

A short description can identify a subject without explaining its stakes. For “Golidocitinib”, the useful work is to connect “pharmaceutical compound” to the records capable of establishing context and consequence.

Evidence profile

Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Dec 26, 2025. The linked authority identifier is Q131696536. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “Golidocitinib”, its source revision and the description used here.
  2. Expand the search: follow Golidocitinib primary sources, Golidocitinib archive and Golidocitinib research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Golidocitinib”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Golidocitinib” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.